ACAD's Quality Score rose 1 point on Tue, Nov 10, to 4. It closed near its high of the day.
Follow ACAD's trial news. Pro members can get an alert when Acadia Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 10.8% today, while its biotech peers are down 1.4%; no story names it yet.
Fell 15% since Nov 4
Down 15% from Nov 4 to Nov 10.
−2Long-term trend
| Since its 2023 high | Down 51% |
| Latest filing | 10-Q, Nov 5 |
TodayNo story names it yet.
Tue Nov 17: UBS Global Biopharma Conference 2026Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed +2.2% on average, higher 2 of 4 times.
No shelf registration or at-the-market program on file in the last three years.
CFO Mark C. Schneyer sold 3,321 shares on Oct 30. 14 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
ACAD is #87 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 87 |
Free cash flow over four quarters: ACAD $82.0M, IRON -$190M.
Expected to report Wed Feb 24, after the close (in 106 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $342.3M, 23% more than a year ago; a profit of $0.31 a share, from $0.42.
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Nuplazid | $202M | – | $178M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)
| Measure | Figure |
|---|---|
| NUPLAZID net product sales | $760M to $775M |
Sales grew 19% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 1.7% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | +2.4% | -1.1% | not yet |
| Aug 4, 2026 | +3.0% | +6.1% | +8.3% |
| May 6, 2026 | +1.9% | +5.0% | +3.3% |
Sales grew every year from 2018 to 2025, to $1.1B. It made a profit in two of the eight years.
RSI 38.4, MACD below signal, below both averages. Not scored.
3 insiders sold $616K across 4 filings in the last 6 months. No open-market buys on record. The newest:
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ACAD is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
“We face, and will continue to face, intense competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies, both in the United States and abroad.”
ACAD scores 4 today, which Breakaway calls Below Average. It is #87 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 15% from Nov 4 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ACAD scores 4 today, which Breakaway calls Below Average (0 to 5). That is #87 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ACAD's 4.
3 insiders sold $616K across 4 filings in the last 6 months. No open-market buys on record. The newest is Mark C. Schneyer, EVP, Chief Financial Officer, who sold $69K on Oct 30. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.